Literature DB >> 12891676

Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs.

Elaine K Perry1, Linda Kilford, Andrew J Lees, David J Burn, Robert H Perry.   

Abstract

The hypothesis that blockade of muscarinic receptors is associated with increased Alzheimer-type pathology was investigated in Parkinson's disease. Amyloid plaque densities were more than 2.5-fold higher in cases treated with antimuscarinic medication in the long term compared with untreated or short-term treated cases (p = 0.005 and 0.00005, respectively). Neurofibrillary tangle densities were also highest in chronic compared with untreated or acute-treated groups (p = 0.02 and 0.05, respectively). The findings, if replicated, have potential implications for the use of anticholinergic medication in elderly Parkinson's disease patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12891676     DOI: 10.1002/ana.10639

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  56 in total

1.  Imidafenacin has no influence on learning in nucleus basalis of Meynert-lesioned rats.

Authors:  Takanobu Yamazaki; Ayako Fukata
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-08-31       Impact factor: 3.000

Review 2.  Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson; Jerry J Buccafusco; Christopher Chapple; William Chet de Groat; Alison D Fryer; Gary Kay; Alan Laties; Neil M Nathanson; Pankaj Jay Pasricha; Alan J Wein
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

3.  Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia.

Authors:  R Ceravolo; D Volterrani; D Frosini; S Bernardini; C Rossi; C Logi; G Manca; L Kiferle; G Mariani; L Murri; U Bonuccelli
Journal:  J Neural Transm (Vienna)       Date:  2006-06-14       Impact factor: 3.575

4.  Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo.

Authors:  Albert A Davis; Jason J Fritz; Jürgen Wess; James J Lah; Allan I Levey
Journal:  J Neurosci       Date:  2010-03-24       Impact factor: 6.167

Review 5.  Rivastigmine in Parkinson's disease dementia: profile report.

Authors:  M Asif A Siddiqui; Antona J Wagstaff
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

6.  Anticholinergics and central nervous system effects: are we confused?

Authors:  David R Staskin; Edward Zoltan
Journal:  Rev Urol       Date:  2007

7.  Muscarinic Receptor M3R Signaling Prevents Efficient Remyelination by Human and Mouse Oligodendrocyte Progenitor Cells.

Authors:  R Ross Welliver; Jessie J Polanco; Richard A Seidman; Anjali K Sinha; Melanie A O'Bara; Zainab M Khaku; Diara A Santiago González; Akiko Nishiyama; Jurgen Wess; M Laura Feltri; Pablo M Paez; Fraser J Sim
Journal:  J Neurosci       Date:  2018-06-29       Impact factor: 6.167

8.  Muscarinic acetylcholine receptor regulates self-renewal of early erythroid progenitors.

Authors:  Gaurang Trivedi; Daichi Inoue; Cynthia Chen; Lillian Bitner; Young Rock Chung; Justin Taylor; Mithat Gönen; Jürgen Wess; Omar Abdel-Wahab; Lingbo Zhang
Journal:  Sci Transl Med       Date:  2019-09-25       Impact factor: 17.956

Review 9.  Anticholinergic medication use and dementia: latest evidence and clinical implications.

Authors:  Shelly L Gray; Joseph T Hanlon
Journal:  Ther Adv Drug Saf       Date:  2016-07-18

10.  Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes.

Authors:  Kaycee M Sink; Joseph Thomas; Huiping Xu; Bruce Craig; Steven Kritchevsky; Laura P Sands
Journal:  J Am Geriatr Soc       Date:  2008-04-01       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.